Ibogaine for Chronic Pain: One Patient’s Recovery After Years of Opioids

The following account is a composite patient narrative drawn from common patterns in ibogaine treatment for chronic pain and opioid dependence. It does not represent a single individual. Names and identifying details are illustrative. All clinical information is based on documented research.

Marcus was 44 years old when he finally told his wife he needed help.

He’d been on opioids for nine years — first prescribed oxycodone after a L4-L5 disc herniation that ended his career in commercial construction. The pain was real. The prescription was legitimate. And for the first two years, the medications worked in the sense that mattered: he could get through the day.

Then they stopped working in that way and started working in another way — the way that made him need them not because they managed his pain but because not having them made everything worse.

By the time Marcus came to our attention, he had done two medically supervised detox programs. Both times, he left with reduced physical dependence and returned to opioids within six weeks. His pain remained. His doctors, after the second detox, declined to restart his prescription. He filled the gap another way.

He found ibogaine through a friend’s recommendation — a construction colleague who had used it two years earlier for a similar trajectory. He spent three months researching before calling us.

The Pain That Outlasted the Prescription

Chronic pain is not a simple problem. Marcus’s disc had been managed surgically. Imaging showed no acute pathology. But the pain continued, and after years of opioid exposure, the situation had become substantially more complicated.

Opioid-induced hyperalgesia is a well-documented phenomenon: prolonged opioid use can paradoxically increase pain sensitivity at the central nervous system level. The same opioids that initially blunted Marcus’s pain were, after years of use, potentially making him more sensitive to it. Stopping opioids can temporarily worsen pain before the nervous system recalibrates — which is one reason abstinence alone often doesn’t resolve chronic pain in opioid-dependent patients.

Marcus had also developed psychological amplification — the emotional and cognitive dimensions of pain that chronic suffering creates. Fear of movement, hypervigilance about physical sensation, depression, sleep disruption, and a narrowed sense of what life can look like. These aren’t imagined problems. They’re measurable neurological and psychological changes that opioids don’t resolve and that brief detox doesn’t address.

What Ibogaine Does Differently

Ibogaine is not a painkiller. What it does that may be relevant to chronic pain and opioid dependence is more complex.

Opioid receptor reset. Ibogaine and its primary metabolite noribogaine act on the mu-opioid receptor in a way that appears to influence receptor downregulation, potentially resetting the number and sensitivity of these receptors toward a pre-dependence baseline. This is part of why ibogaine can dramatically reduce the physical symptoms of opioid withdrawal.

GDNF upregulation. Research has documented that ibogaine stimulates the release of glial cell line-derived neurotrophic factor (GDNF) — a protein that promotes the survival and function of dopaminergic neurons. Elevated GDNF has been associated with reduced drug-seeking behavior in animal models and may be part of why ibogaine’s anti-craving effects appear to outlast its direct pharmacological action.

NMDA receptor antagonism. Ibogaine acts as an NMDA receptor antagonist, similar in mechanism to ketamine — a drug used specifically for treatment-resistant pain and depression. NMDA antagonism affects central sensitization, the neural process by which chronic pain becomes self-sustaining even after the original injury has resolved.

The convergence of these mechanisms doesn’t guarantee pain relief — and it’s important to say that directly. But it does create a pharmacological rationale for why some patients with chronic pain and opioid dependence report meaningful changes in both dimensions after ibogaine treatment.

If you or someone close to you needs help right now, SAMHSA’s national helpline is free, confidential and staffed 24/7 on 1-800-662-HELP.

Before the Session

Marcus went through Psychedelic Connect’s vetting process to find a medical clinic in Mexico. That process involved a phone consultation to assess his history and goals, a referral to a clinic with a board-certified internist on staff, a pre-treatment intake with the clinic physician including detailed medical history and medication reconciliation, a mandatory EKG at a local cardiologist two weeks before his treatment date, bloodwork covering liver enzymes, metabolic panel, and electrolytes, and a required taper of his opioid use in the week before treatment.

He arrived at the clinic on a Thursday. The session was planned for Friday evening.

The night before the session, Marcus told us later, he almost left. “I’d read everything I could find and I still didn’t really know what I was walking into. The doctors were genuinely reassuring. They’d done this hundreds of times. But it’s still a choice you make alone.”

The Session Itself

Ibogaine sessions last between 8 and 24 hours depending on the dose and the individual’s metabolism. Marcus received an initial test dose, then a full flood dose after the clinic confirmed he was tolerating it. Continuous cardiac monitoring ran throughout.

What he described in a follow-up call three weeks later included a sustained encounter with his own life narrative that felt less like hallucination and more like review, and a point in the early morning hours when something about his relationship to the pain — not the pain itself, but the fear around it — felt different.

“I don’t know how to explain it without sounding like I’m making it up. The pain was still there in the morning. But I was — less organized around protecting it.”

After: What Changed and What Didn’t

Three weeks after treatment, Marcus was not on opioids. The withdrawal he had dreaded — which had driven him back to opioids both times after his previous detox programs — was manageable. He rated it at a 3 or 4 out of 10 compared to 8 or 9 in previous attempts.

Six months after treatment, he was still not on opioids. His pain, measured on a standard 0–10 numeric scale, had dropped from its pre-treatment average of 6–7 to a consistent 3–4. Whether ibogaine directly reduced his pain or broke the opioid-withdrawal cycle that was amplifying his pain — or both — is impossible to say from a single case. He continued integration sessions with a therapist familiar with psychedelic experiences for six months after treatment.

The Honest Limitations

Ibogaine is not a pain cure. Some patients with chronic pain report no reduction in pain intensity after treatment. What ibogaine consistently does when used appropriately is interrupt the opioid dependence cycle. Patients should expect significant reduction in opioid withdrawal severity and craving (well-documented), variable effects on underlying pain (some patients report improvement, some do not), and a period of integration work required to sustain any shift in the psychological relationship to pain.

Integration support is not optional. The neuroplastic window that ibogaine creates closes. What you do with it while it’s open determines durability.

If This Story Sounds Familiar

If Marcus’s story maps onto your own — chronic pain, opioid prescriptions that became dependence, failed detox attempts — we can help you assess whether ibogaine is appropriate for your specific situation.

Read more at ibogaine for chronic pain and the ibogaine safety guide. Call (866) 435-7057 or schedule a consultation here.

Medical Disclaimer: The content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The narrative above is a composite illustration and not a clinical case study. Always consult a qualified physician before pursuing ibogaine treatment. Individual results vary significantly. Ibogaine carries cardiac risk and is contraindicated in certain populations.